115 related articles for article (PubMed ID: 38762494)
1. Fruquintinib-induced renal-limited thrombotic microangiopathy: a case report.
Zhao R; Fan R; Pan Y; Han Y; Wang Y; Chen W
BMC Nephrol; 2024 May; 25(1):170. PubMed ID: 38762494
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib-induced renal-limited thrombotic microangiopathy: a case report and review of literatures.
Yin Q; Guo N; Zhou X; Xu H; Lei S; Fu P; Zhong H
BMC Nephrol; 2022 Mar; 23(1):112. PubMed ID: 35305559
[TBL] [Abstract][Full Text] [Related]
3. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report.
Yamada R; Okawa T; Matsuo K; Suzuki M; Mori N; Mori K
BMC Nephrol; 2019 Jan; 20(1):14. PubMed ID: 30634936
[TBL] [Abstract][Full Text] [Related]
4. Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Nishikubo M; Shimomura Y; Hiramoto N; Sawamura N; Yamaguchi T; Hara S; Ishikawa T
BMC Nephrol; 2021 May; 22(1):175. PubMed ID: 33980166
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
6. Two cases of idiopathic steroid-resistant nephrotic syndrome complicated with thrombotic microangiopathy.
Nishi K; Sato M; Ogura M; Okutsu M; Ishikura K; Kamei K
BMC Nephrol; 2020 Aug; 21(1):323. PubMed ID: 32746791
[TBL] [Abstract][Full Text] [Related]
7. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy.
Pfister F; Amann K; Daniel C; Klewer M; Büttner A; Büttner-Herold M
Histopathology; 2018 Dec; 73(6):990-1001. PubMed ID: 30014486
[TBL] [Abstract][Full Text] [Related]
8. Pegylated Liposomal Doxorubicin Causes Kidney-limited Thrombotic Microangiopathy.
Glezerman I; Salvatore S; Tap W; Kelly C; Brauer Ornelas CM; Shaikh A
Am J Kidney Dis; 2024 Apr; 83(4):549-553. PubMed ID: 37839689
[TBL] [Abstract][Full Text] [Related]
9. Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: A renal biopsy and autopsy case report.
Cassol CA; Williams MPA; Caza TN; Rodriguez S
Medicine (Baltimore); 2019 Sep; 98(39):e17148. PubMed ID: 31574818
[TBL] [Abstract][Full Text] [Related]
10. Influenza-induced thrombotic microangiopathy in a patient with cancer on proteasome inhibitor: a diagnostic dilemma.
Hamad CD; Hoelscher ZC; Tchakarov A; Kala J
CEN Case Rep; 2022 Aug; 11(3):321-327. PubMed ID: 34997535
[TBL] [Abstract][Full Text] [Related]
11. A nationwide cross-sectional analysis of thrombotic microangiopathy in the Japan Renal Biopsy Registry (J-RBR).
Katsuno T; Ito Y; Kagami S; Kitamura H; Maruyama S; Shimizu A; Sugiyama H; Sato H; Yokoyama H; Kashihara N
Clin Exp Nephrol; 2020 Sep; 24(9):789-797. PubMed ID: 32415379
[TBL] [Abstract][Full Text] [Related]
12. Thrombotic microangiopathy, cancer, and cancer drugs.
Izzedine H; Perazella MA
Am J Kidney Dis; 2015 Nov; 66(5):857-68. PubMed ID: 25943718
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine-induced thrombotic microangiopathy with nephrotic syndrome.
Katagiri D; Hinoshita F
CEN Case Rep; 2018 Nov; 7(2):217-220. PubMed ID: 29766468
[TBL] [Abstract][Full Text] [Related]
14. Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema.
Kikuchi Y; Odashima Y; Yoshikawa K; Oda T; Tanaka F; Oikawa H; Ishigaki Y; Asahi K
BMC Nephrol; 2022 Oct; 23(1):348. PubMed ID: 36309669
[TBL] [Abstract][Full Text] [Related]
15. Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.
Leurs A; Gnemmi V; Lionet A; Renaud L; Gibier JB; Copin MC; Hachulla E; Hatron PY; Launay D; Fajgenbaum D; Terriou L
Front Immunol; 2019; 10():1489. PubMed ID: 31316523
[No Abstract] [Full Text] [Related]
16. De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus.
Cortina G; Trojer R; Waldegger S; Schneeberger S; Gut N; Hofer J
Pediatr Nephrol; 2015 Apr; 30(4):693-7. PubMed ID: 25577332
[TBL] [Abstract][Full Text] [Related]
17. Association of vascular endothelial growth factor and renal thrombotic microangiopathy-like lesions in patients with Castleman's disease.
Sun PP; Yu XJ; Wang SX; Zhou XJ; Qu L; Zhang F; Ma YY; Liu G; Yang L
Nephrology (Carlton); 2020 Feb; 25(2):125-134. PubMed ID: 31264312
[TBL] [Abstract][Full Text] [Related]
18. Renal thrombotic microangiopathy during nintedanib treatment for idiopathic pulmonary fibrosis
.
Inoue D; Nishi H; Honda K; Ishii T; Abe H; Sato M; Nangaku M
Clin Nephrol; 2020 Jan; 93(1):47-50. PubMed ID: 31699213
[TBL] [Abstract][Full Text] [Related]
19. Pathologic Correlation with Renal Dysfunction after Intravitreal Injections of Vascular Endothelial Growth Factor Antagonists.
Zhang PL; Raza S; Li W; Kanaan HD
Ann Clin Lab Sci; 2021 Nov; 51(6):875-882. PubMed ID: 34921042
[TBL] [Abstract][Full Text] [Related]
20. Thrombotic microangiopathy associated with Valproic acid toxicity.
Hebert SA; Bohan TP; Erikson CL; Swinford RD
BMC Nephrol; 2017 Aug; 18(1):262. PubMed ID: 28774273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
